Evidence map›Paper›PMID 39095596›Full record

Trial reportNature medicine2024

The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial.

Iokfai Cheang, Wenming Yao, Yanli Zhou, Xu Zhu, Gehui Ni, Xinyi Lu, Shengen Liao, Rongrong Gao, Fang Zhou, Jiangang Shen and 30 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Review
  12. Observational
  13. Injectable natural hydrogel-loaded TaCommunications chemistry · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Frontiers in pharmacology · 2026
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Iokfai Cheang *State Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Wenming Yao *State Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Yanli Zhou *State Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Xu ZhuState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.ORCID http://orcid.org/0000-0002-4347-3639
Gehui NiState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Xinyi LuState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Shengen LiaoState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Rongrong GaoState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Fang ZhouState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Jiangang ShenSchool of Chinese Medicine, The University of Hong Kong, Hong Kong SAR, China.
Alice Yeuk Lan LeungSchool of Chinese Medicine, The University of Hong Kong, Hong Kong SAR, China.
Meng JiangRenji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Hong KongSichuan Provincial People's Hospital, Chengdu, China.
Ling BaiThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ailiman MahemutiFirst Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Haitao YuanShandong Provincial Hospital, Jinan, China.
Yu-Gang DongThe First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Chun-Ka WongQueen Mary Hospital, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Qinghua XuLiaocheng People's Hospital, Liaocheng, China.
Gaoxing ZhangJiangmen Central Hospital, Jiangmen, China.
Jianhua WuXiuyan Manchu Autonomous County Central Peoples Hospital, Anshan, China.
Qi LuAffiliated Hospital of Nantong University, Nantong, China.
Junhai ZhangWeixian Hospital of Traditional Chinese Medicine, Weixian, China.
Chunxi ChaXinjiang Production and Construction Corps First Division Hospital, Aksu, China.
Qian RenSunsimiao Hospital of BUCM, Tongchuan, China.
Lu FuThe First Hospital of Harbin Medical University, Harbin, China.
Bing WangZouping People's Hospital, Zouping, China.
Yongshun XuWorkers' Hospital of Handan Iron and Steel Group Co., Handan, China.
Houxiang HuAffiliated Hospital of North Sichuan Medical College, Nanchong, China.
Jing DongThe Second Affiliated Hospital of Shaanxi Medical University of Chinese Medicine, Xianyang, China.
Zhuo ShangThe Second People's Hospital of Bengbu, Bengbu, China.
Chaoping YuPidu District People's Hospital, Chengdu, China.
Songsen LiLuoyang Central Hospital, Luoyang, China.
Chen YaoPeking University Clinical Research Institute, Beijing, China.
Lingling GaoPeking University Clinical Research Institute, Beijing, China.
Haifeng ZhangState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. haifeng_zhang@163.com.
Anthony RosenzweigInstitute for Heart and Brain Health, University of Michigan Medical Center, Ann Arbor, MI, USA. anthros@med.umich.edu.ORCID http://orcid.org/0000-0001-6387-0386
Zhenhua JiaState Key Laboratory for Innovation and Transformation of Luobing Theory, Hebei Clinical Research Center of Cardiovascular Disease of Traditional Chinese Medicine, Shijiazhuang, China. jzhjiazhenhua@163.com.ORCID http://orcid.org/0000-0001-5132-1099
Xinli LiState Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. xinli3267@yeah.net.ORCID http://orcid.org/0000-0002-6794-1468
QUEST Trial Committees and Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous findings have indicated the potential benefits of the Chinese traditional medicine Qiliqiangxin (QLQX) in heart failure. Here we performed a double-blind, randomized controlled trial to evaluate the efficacy and safety of QLQX in patients with heart failure and reduced ejection fraction (HFrEF). This multicenter trial, conducted in 133 hospitals in China, enrolled 3,110 patients with HFrEF with NT-proBNP levels of ≥450 pg ml

Indexed as

Drugs, Chinese HerbalHeart FailureStroke VolumeAgedDouble-Blind MethodFemaleHospitalizationHumansMaleMedicine, Chinese TraditionalMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsTreatment OutcomeDrugs, Chinese HerbalNatriuretic Peptide, BrainPeptide Fragmentsqiliqiangxin

Identifiers

PMID39095596
PMCPMC11333273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.